Anup Kumar Trikannad

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

UAMS

Also affiliated: University of Arkansas Medical Center (2025); Willis-Knighton Cancer Center (2026); Winrock International (United States) (2026); Winthrop Rockefeller Foundation (2024); Union Hospital (2022)

Faculty Researcher

3 h-index 26 pubs 51 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Anup Kumar Trikannad's research focuses on the intersection of hematologic malignancies, particularly multiple myeloma, and the management of infections and immune responses in patients undergoing advanced therapies. His work investigates the impact of interventions such as Intravenous Immunoglobulin (IVIG) supplementation on infection-free survival in patients receiving BCMA-directed bispecific antibody therapy and teclistamab therapy for multiple myeloma. Trikannad also examines the prognostic significance of lymphocyte counts and immune composition in patients undergoing bispecific antibody therapy for relapsed or refractory multiple myeloma. His publications address other oncologic topics, including mediastinal lymphadenopathy following COVID-19 vaccination in oncology patients and the potential stem cell origins of cancer with clinical implications for therapy development. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including César Sánchez, Hira Imad Cheema, J. Curran Henson, and Ankur Varma, on multiple shared publications.

Metrics

h-index: 3
Publications: 26
Citations: 51

Selected Publications

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study (2026)

Cancer Investigation DOI OpenAlex
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
26-A-9693-ACC PREDICTION OF 1-YEAR MAJOR ADVERSE CARDIAC EVENTS IN CAR-T RECIPIENTS USING RISK SCORE MODELING: EXPANDED WHOLE-COHORT ANALYSIS (2026)

Journal of the American College of Cardiology DOI OpenAlex
26-A-11133-ACC CYTOKINE RELEASE SYNDROME-GUIDED RISK MODELS REDEFINE CARDIOTOXICITY SURVEILLANCE: OPTIMIZING DETECTION OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION AND ADVERSE CARDIOVASCULAR EVENTS AFTER CAR-T THERAPY (2026)

Journal of the American College of Cardiology DOI OpenAlex
26-CCC-15772-ACC A CASE OF ACUTE PROTRACTED NON-ISCHEMIC CARDIOMYOPATHY PRECEDING DEVELOPMENT OF BUNDLE BRANCH RE-ENTRANT TACHYCARDIA PRECIPITATED BY CYTOKINE RELEASE SYNDROME FOLLOWING CHIMERIC ANTIGEN T-CELL THERAPY (2026)

Journal of the American College of Cardiology DOI OpenAlex
Critical platelet shortages and a single Institution's experience with split platelet transfusions: Can you get by with just half a unit? (2025)

Blood DOI OpenAlex
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025)

Journal of Clinical Oncology DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

Journal of Clinical Oncology DOI OpenAlex
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)

Blood Cancer Journal 32 citations DOI OpenAlex
PREDICTORS OF ADVERSE CARDIOVASCULAR EVENTS AFTER CHIMERIC ANTIGEN T-CELL (CAR-T) THERAPY (2025)

Journal of the American College of Cardiology DOI OpenAlex
Demographic analysis of survival trends in squamous cell carcinoma of the upper 1/3 of the esophagus: a population-based study (2024)

Diseases of the Esophagus DOI OpenAlex